Amgen and Allergan plc announced results from a phase III study evaluating efficacy and safety of biosimilar ABP 980 compared with trastuzumab in patients with human epidermal growth factor receptor 2-positive early breast cancer.
Niraparib achieved its primary endpoint in a phase III ovarian cancer trial, demonstrating prolonged progression-free survival compared to placebo among patients who are germline BRCA mutation carriers; among patients who are not germline BRCA mutation carriers, but who have homologous recombination deficient tumors as determined by the Myriad myChoice HRD test; and overall in patients who are not germline BRCA mutation carriers.
The U.S. News & World Report rankings of the best cancer hospitals for 2016 brought no great surprises. The top four cancer centers did not change from last year:
Foundation Medicine approached NCI with the idea to make their data useful in the public domain.
Making data broadly available to clinicians and researchers has always been a part of the mission for Foundation Medicine Inc., said Michael Pellini, the company's CEO.
When the Genomic Data Commons opened June 6, the $20 million portal that consolidates NCI's datasets contained genomic information from 14,500 patients.
At a June 21 joint meeting, the NCI Board of Scientific Advisors and the National Cancer Advisory Board approved three concepts and deferred one:
MD Anderson surveyed 450 faculty, trainees and staff Sept. 29 through Nov. 10, 2015, to gather their opinions on campus-carry gun laws. Here's what they said:
In response to Texas concealed carry laws, MD Anderson proposed a plan that would allow guns only in designated buildings—the rest, specifically areas of worship and hospital facilities, are gun-exclusion zones.
This may not be the sort of targeted therapy Texas healthcare institutions wish to be known for, but starting Aug. 1, visitors to designated areas at MD Anderson Cancer Center, UT Southwestern, and UT Health Science Center at San Antonio will be able to carry their guns.
